[1] 刘晓丽,姜达,崔彦芝.三阴性乳腺癌雄激素受体研究进展[J].中国癌症杂志,2016,26(5):466-470.
[2] 彭燕.三阴性乳腺癌潜在的肿瘤预后生物标志[J].北京大学学报:医学版,2012,44(5):666-672.
[3] 智英辉,尼杰,田秀芳,等.雄激素受体在三阴性乳腺癌的表达及其预后意义[J].重庆医学,2012,41(27):2812-2815.
[4] 田慧玲,周凤华,郑洁,等.Ki-67、AR及FRA在三阴性乳腺癌中的表达及意义[J].现代肿瘤医学,2014,22(4):830-833.
[5] 李永,田沛琦,崔树德,等.不同AR状态三阴性乳腺癌新辅助化疗疗效分析[J].河南医学研究,2015,24(7):45-46.
[6] 马蓉,姚宇锋,龚建平,等.雄激素受体在三阴性乳腺癌中的表达及其预后价值[J].肿瘤预防与治疗,2013,26(3):122-124.
[7] Tang D,Xu S,Zhang Q,et al.The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer[J].Med Oncol,2012,29(2):526-533.
[8] Luo X,Shi YX,Li ZM,et al.Expression and clinical significance of androgen receptor in triple negative breast cancer[J].Chin J Cancer,2010,29(6):585-590.
[9] Mrklic I, Pogorelic Z,Capkun V,et al.Expression of androgen receptors in triple negative breast carcinomas[J].Acta Histochem,2013,115(4):344-348.
[10] Gonzalez-Angulo AM,Stemke-Hale K,Palla SL,et al.Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer[J].Clin Cancer Res,2009,15(7):2472-2478.
[11] He J,Peng R,Yuan Z,et al.Prognostic value of androgen receptor expression in operable triple-negative breast cancer:a retrospective analysis based on a tissue microarray[J].Med Oncol,2012,29(2):406-410.
[12] Park S,Koo JS,Kim MS,et al.Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers[J].Ann Oncol,2011,22(8):1755-1762.
[13] RicciardiG RR,Adamo B,Ieni A,et al.Androgen receptor (AR),E-cadherin,and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients[J].PLoS One,2015,10(6):10-18.
[14] Hilborn E,Gacic J,Fornander T,et al.Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer[J].Br J Cancer,2016,114(3):248-255.
[15] Pietri E,Conteduca V,Andreis D,et al.Androgen receptor signaling pathways as a target for breast cancer treatment[J].Endoc Relat Cancer,2016,23(10):R485-R498.
[16] Payandeh M,Shazad B,Madani S,et al.Androgen receptor expression and its correlation with other risk factors in triple negative breast cancers:a report from Western Iran[J].Asian Pac J Cancer Prev,2016,17(7):3321-3324.
[17] Liu YX,Wang KR,Xing H,et al.Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers[J].Oncol Lett,2016,12(2):1240-1256.
[18] Jiang HS,Kuang XY,Sun WL,et al.Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status[J].Oncotarget,2016,7(27):41285-41293.
[19] Bianchini G,Balko JM,Mayer I A,et al.Triple-negative breast cancer:challenges and opportunities of a heterogeneous disease[J].Nat Rev Clin Oncol,2016,13(11):674-690.
[20] Thakkar A,Wang B,Picon-Ruiz M,et al.Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer[J].Breast Cancer Res Treat,2016,157(1):77-90.
[21] Kim S,Moon BI,Lim W,et al.Expression patterns of GATA3 and the androgen receptor are strongly correlated in patients with triple-negative breast cancer[J].Hum Pathol,2016,55:190-195.
[22] Cinkaya A,Akin M,Sengul A.Evaluation of treatment outcomes of triple-negative breast cancer[J].J Cancer Res Ther,2016,12(1):150-154.
[23] 陈健,张旭,田茹,等.不同ER、PR状态乳腺癌中AR的表达及其意义[J].临床与实验病理学杂志,2010,26(1):52-55.
[24] 方茅,翁泽平,关弘,等.三阴性乳腺癌组织DJ-1和PTEN及AR表达与预后相关性分析[J].中华肿瘤防治杂志,2013,20(10):761-764.
[25] 陈健,张旭,田茹,等.雄激素受体在乳腺癌中的表达及其与雌、孕激素受体和HER2的关系[J].中华病理学杂志,2010,39(11):743-746.
[26] Pistelli M,Ballatore Z,Santinelli A,et al.Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer[J].Oncol Rep,2016,36(2):755-762.
[27] 迪力夏提·金斯汗,吐鲁洪·沙列尔,赵倩.EZH2抑制剂DZNeP对人乳腺癌细胞增殖、凋亡及相关信号通路的影响[J].中国老年学杂志,2016,36(16):3877-3879.
[28] 乔伟强,潘琳琳,寇长贵,等.局部晚期乳腺癌新辅助化疗病理完全缓解与预后相关性的Meta分析[J].中国老年学杂志,2016,36(16):3982-3985. |